Revance The (RVNC)

Currency in USD
3.650
0.000(0.00%)
Closed·
Showing Revance The historical data. For real-time data please try another search
Day's Range
3.6503.660
52 wk Range
2.3006.650
Key Statistics
Prev. Close
3.65
Open
3.65
Day's Range
3.65-3.66
52 wk Range
2.3-6.65
Volume
4.12M
Average Volume (3m)
3.01M
1-Year Change
14.06%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Revance The News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Revance The Company Profile

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. As of February 6, 2025, Revance Therapeutics, Inc. operates as a subsidiary of Crown Laboratories, Inc.

Employees
597

Revance The SWOT Analysis


Tender Offer Shake-up
Crown's $6.66 per share cash offer for Revance Therapeutics represents an 89% premium, valuing the company at $924 million enterprise value
Financial Challenges
Despite undervaluation, Revance faces negative free cash flow, substantial debt, and projected negative EPS, raising concerns about future stability
Industry Positioning
Revance maintains an Overweight rating with strong revenue growth, reflecting positive industry sentiment and potential growth opportunities
Regulatory Hurdles
Acquisition completion hinges on shareholder approval and regulatory clearance, introducing uncertainty to Revance's future trajectory
Read full SWOT analysis

Revance The Earnings Call Summary for Q2/2024

  • Q2 net revenue reached $65.4M, up 20% YoY; on track for $280M 2024 guidance
  • Aesthetics division: 65% increase in units sold, 27% rise in net product revenue
  • DAXXIFY for cervical dystonia launched in May; modest revenue expected in 2024
  • Company projects positive adjusted EBITDA by 2025
  • International expansion plans under evaluation, including partnerships in markets like Australia
Last Updated: 09/08/2024, 22:14
Read Full Transcript

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-- / -0.2415
Revenue / Forecast
-- / 72.00M
EPS Revisions
Last 90 days

RVNC Income Statement

People Also Watch

1.460
QSI
-1.35%
7.530
QMCO
-5.99%
0.1961
GWAV
-3.35%
2.980
LAES
-3.56%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.